MoneyWorks4Me

Beryl Drugs informs about annual report

03 Sep 2021 Evaluate

Beryl Drugs has informed about submission of Annual Report for the Financial Year 2020-21 convening the 28th Annual General Meeting as required under Regulation 34(1) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above information is a part of company’s filings submitted to BSE.

Beryl Drugs Share Price

23.99 1.07 (4.67%)
31-Aug-2026 12:25 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1922.95
Dr. Reddys Labs. 1176.45
Cipla 1416.90
Lupin 2156.60
Zydus Lifesciences 1163.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: